Zealand Pharma A/S – American Depositary Shares (ZEAL) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL) from a buy rating to a hold rating in a research note published on Saturday, January 13th.

According to Zacks, “Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark. “

Several other equities analysts have also recently weighed in on ZEAL. Needham & Company LLC reiterated a buy rating and set a $26.00 price objective on shares of Zealand Pharma A/S – American Depositary Shares in a report on Monday, October 16th. Goldman Sachs Group initiated coverage on Zealand Pharma A/S – American Depositary Shares in a report on Wednesday, September 27th. They set a buy rating on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $24.75.

Shares of Zealand Pharma A/S – American Depositary Shares (NASDAQ ZEAL) opened at $16.34 on Friday. Zealand Pharma A/S – American Depositary Shares has a 12-month low of $12.45 and a 12-month high of $20.37.

Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.13. analysts predict that Zealand Pharma A/S – American Depositary Shares will post -1.46 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. Royce & Associates LP acquired a new position in shares of Zealand Pharma A/S – American Depositary Shares during the 3rd quarter worth approximately $1,152,000. Jane Street Group LLC acquired a new position in shares of Zealand Pharma A/S – American Depositary Shares during the 3rd quarter worth approximately $386,000. Finally, Susquehanna International Group LLP acquired a new position in shares of Zealand Pharma A/S – American Depositary Shares during the 3rd quarter worth approximately $3,185,000. 13.33% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/05/zealand-pharma-as-american-depositary-shares-zeal-downgraded-by-zacks-investment-research-to-hold.html.

Zealand Pharma A/S – American Depositary Shares Company Profile

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.

Get a free copy of the Zacks research report on Zealand Pharma A/S – American Depositary Shares (ZEAL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zealand Pharma A/S - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply